Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

por Lin, Nancy U., Pegram, Mark, Sahebjam, Solmaz, Ibrahim, Nuhad, Fung, Anita, Cheng, Anna, Nicholas, Alan, Kirschbrown, Whitney, Kumthekar, Priya
Publicado 2021

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

por Quartino, Angelica L., Li, Hanbin, Kirschbrown, Whitney P., Mangat, Ranvir, Wada, D. Russell, Garg, Amit, Jin, Jin Y., Lum, Bert
Publicado 2018

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-p...

por Wang, Bei, Deng, Rong, Hennig, Stefanie, Badovinac Crnjevic, Tanja, Kaewphluk, Monika, Kågedal, Matts, Quartino, Angelica L., Girish, Sandhya, Li, Chunze, Kirschbrown, Whitney P.
Publicado 2021

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics

por Liu, Stephanie N., Lu, Tong, Jin, Jin Y., Li, Chunze, Girish, Sandhya, Melnikov, Fjodor, Badovinac Crnjevic, Tanja, Machackova, Zuzana, Restuccia, Eleonora, Kirschbrown, Whitney P.
Publicado 2021

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

por Kirschbrown, Whitney P., Wang, Bei, Nijem, Ihsan, Ohtsu, Atsushi, Hoff, Paulo M., Shah, Manish A., Shen, Lin, Kang, Yoon-Koo, Alsina, Maria, Girish, Sandhya, Garg, Amit
Publicado 2019

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

por Kirschbrown, Whitney P., Wynne, Chris, Kågedal, Matts, Wada, Russ, Li, Hanbin, Wang, Bei, Nijem, Ihsan, Badovinac Crnjevic, Tanja, Gasser, Helena, Heeson, Sarah, Eng‐Wong, Jennifer, Garg, Amit
Publicado 2018

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

por Wu, Huali, Infante, Jeffrey R, Keedy, Vicki L, Jones, Suzanne F, Chan, Emily, Bendell, Johanna C, Lee, Wooin, Kirschbrown, Whitney P, Zamboni, Beth A, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L, Burris, Howard A, Zamboni, William C
Publicado 2015

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

por Kirschbrown, Whitney P., Kågedal, Matts, Wang, Bei, Lindbom, Lars, Knott, Adam, Mack, Rachelle, Monemi, Sharareh, Nijem, Ihsan, Girish, Sandhya, Freeman, Christie, Fumagalli, Debora, McConnell, Robin, Jerusalem, Guy, Twelves, Chris, Baselga, José, von Minckwitz, Gunter, Bines, José, Garg, Amit
Publicado 2019